The monoclonal antibody will be engineered by GBI’s collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma.
GBI Process Development Vice President Muctarr Sesay said the project represents ‘one-stop-shopping’ for their clients as they can take a client’s cDNA, engineer the cell line with the help of one of their collaborative partners, Rafagen.
Rafagen in turn is believed to provide GBI with three stable, high-producing clones, which will be evaluated to select the highest producer and create a Research Cell Bank and start manufacturing the antibody of interest.
Goodwin Biotechnology is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines with experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies.